---
figid: PMC7147660__cm9-133-853-g001
figtitle: PD-1/PD-L1 pathway and anti-PD-1/PD-L1 agents combination strategies in
  breast cancer
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC7147660
filename: cm9-133-853-g001.jpg
figlink: pmc/articles/PMC7147660/figure/F1/
number: F1
caption: 'PD-1/PD-L1 pathway and anti-PD-1/PD-L1 agents combination strategies in
  breast cancer. The binding of PD-L1 to PD-1 attenuates lymphocyte activation and
  inhibits the immune response. A2AR: Adenosine A2a receptor; ATP: Adenosine triphosphate;
  CDK4/6: Cyclin-dependent kinase 4/6; CRT: Calreticulin; E2F: Transcription factor
  E2F; HER2: Human epidermal growth factor receptor 2; HMGB1: Mobility group box protein
  B1; ICD: Immune cell death; IDO1: Indoleamine 2,3-dioxygenase 1; JAK/STAT: Janus
  kinase/signal transducer and activator of transcription; Krn: Kynurenine; MHC-Ag:
  Major histocompatibility complex-antigen; ORR: Overall response rate; PARP: Poly
  (ADP-ribose) polymerase; PD-1: Programmed cell death-1; PD-L1: Programmed cell death
  ligand-1; PI3K3K/Akt: Phosphatidylinositol 3-kinase/protein kinase-B; Rb: Retinoblastoma;
  RAS/MAPK: RAS/mitogen-activated protein kinase; T-DM1: Ado-trastuzumab emtansine;
  Trp: Tryptophan; TCR: T cell receptor; TMB: Tumor mutation burden.'
papertitle: 'Breast cancer immunology and immunotherapy: targeting the programmed
  cell death protein-1/programmed cell death protein ligand-1.'
reftext: Jing Zhao, et al. Chin Med J (Engl). 2020 Apr 5;133(7):853-862.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9543303
figid_alias: PMC7147660__F1
figtype: Figure
redirect_from: /figures/PMC7147660__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7147660__cm9-133-853-g001.html
  '@type': Dataset
  description: 'PD-1/PD-L1 pathway and anti-PD-1/PD-L1 agents combination strategies
    in breast cancer. The binding of PD-L1 to PD-1 attenuates lymphocyte activation
    and inhibits the immune response. A2AR: Adenosine A2a receptor; ATP: Adenosine
    triphosphate; CDK4/6: Cyclin-dependent kinase 4/6; CRT: Calreticulin; E2F: Transcription
    factor E2F; HER2: Human epidermal growth factor receptor 2; HMGB1: Mobility group
    box protein B1; ICD: Immune cell death; IDO1: Indoleamine 2,3-dioxygenase 1; JAK/STAT:
    Janus kinase/signal transducer and activator of transcription; Krn: Kynurenine;
    MHC-Ag: Major histocompatibility complex-antigen; ORR: Overall response rate;
    PARP: Poly (ADP-ribose) polymerase; PD-1: Programmed cell death-1; PD-L1: Programmed
    cell death ligand-1; PI3K3K/Akt: Phosphatidylinositol 3-kinase/protein kinase-B;
    Rb: Retinoblastoma; RAS/MAPK: RAS/mitogen-activated protein kinase; T-DM1: Ado-trastuzumab
    emtansine; Trp: Tryptophan; TCR: T cell receptor; TMB: Tumor mutation burden.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - L1CAM
  - RPS10
  - PSMD6
  - HMGB1
  - GNPTAB
  - CALCR
  - CALR
  - SLC6A8
  - ATP8A2
  - KRTAP5-9
  - WDTC1
  - ADO
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD274
  - IDO1
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - HLA-C
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - CDK4
  - CDK6
  - CCND1
  - CCND2
  - CCND3
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - ENTPD1
  - Hmgb1
  - Calr
  - Slc6a8
  - Wdtc1
  - Mdga2
  - Ado
  - Trav6-3
  - Cd274
  - Ido1
  - Pdcd1
  - Parp1
  - Cdk4
  - Cdk6
  - Entpd1
  - RpS20
  - RpS10a
  - Dsp1
  - crt
  - ATPsynbeta
  - Atpalpha
  - Krn
  - adp
  - ado
  - Stat92E
  - Tcr
  - Mhc
  - zip
  - mRpL55
  - Parp
  - CycD
  - norpA
  - Pka-C1
  - rb
  - ebi
  - E2f2
  - E2f1
  - ATP
  - ADP
  - Trp
  - adenosine
  - TCR
  - CPI-444
  - TMB
  - CDKA
  - ICD
---
